Genitourinary-Cancer-Meeting
Trending
Immunotherapy in non muscle invasive bladder cancer #GU16
How does CYP17 inhibitors and novel androgen receptor inhibitors affect current treatment paradigms for advanced prostate cancer
Resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer
Does treatment for prior cancer develop secondary bladder cancer #gu16
Clinical and pathological factors that can influence outcomes in upper tract urothelial cancer #GU16
CheckMate 025 Phase III Trial Dr. Toni Choueiri
Annual Meeting GU 2016 Genetic Testing in Prostate Cancer
Annual Meeting GU 2016 Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer
Inhibiting autophagy in bladder cancer #GU16
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
My videos
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.
175 Views
2 years ago
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Clinical and pathological factors that can influence outcomes in upper tract urothelial cancer #GU16
Annual Meeting GU 2016 Role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer
Annual Meeting GU 2016 Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers
Annual Meeting GU 2016 Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab
Annual Meeting GU 2016 Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer
Annual Meeting GU 2016 Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer
Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer Annual Meeting GU 2016
Ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer
Molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer.
